Biogen To Launch Phase III Alzheimer’s Prevention Study

Jan 30 2019

• By Eleanor Malone

Listen to this article

The firm announced plans to begin a Phase III study of aducanumab to prevent or delay the onset of Alzheimer’s, but refused to discuss ongoing studies during its fourth quarter earnings call.

New Study To Test Early Use Of Aducanumab • Source: Shutterstock

Biogen Inc. will launch a new Phase III study of its anti-amyloid-beta antibody aducanumab for early use to prevent or delay the clinical onset of Alzheimer’s disease. In a fourth-quarter conference call in which executives stood firm in their policy of refusing to comment on whether (or when) they might announce details of any interim or futility analysis of the heavily watched ongoing EMERGE and ENGAGE Phase III studies of aducanumab in early Alzheimer’s, observers had to settle for hints of progress in the Alzheimer’s arena.

Biogen Revenue Details At A Glance

2018 revenues $13.5bn (+10%)

Unveiling 2018 figures that showed it performed solidly if not spectacularly, Biogen said 2019 revenues would rise slightly from $13.5bn...

More from Neurological

Evidence Growing For GLP-1s To Treat Alzheimer’s And Parkinson’s
Mar 10 2025
• By Andrew McConaghie
GLP-1 receptor agonists could play a big role in tackling neurodegeneration and a new academic study has raised expectations of Novo Nordisk’s latest semaglutide Phase III results
As More DLL3 Bispecifics Advance, Doctors Are Adjusting To CRS, ICANS
Mar 10 2025
• By Mandy Jackson
Amgen’s Imdelltra for small-cell lung cancer is one of two bispecific T-cell engagers approved for solid tumors, but data at the WCLC meeting show other DLL3-targeting BiTEs may be on the way.
Novo Nordisk’s Semaglutide Shows Promise In Hidradenitis Suppurativa
Mar 10 2025
• By Andrew McConaghie
An academic study of GLP-1 agonist showed promise in patients with the painful skin condition but with no signs that the Danish drugmaker will pursue the indication, smaller players in the space may be interested.
Biogen Joins Molecular Glue Degrader Club with Neomorph Pact--Test-1
Dec 10 2024
• By Saba Afreen
As it posts third-quarter numbers that again reveal the decline of revenues from its multiple sclerosis portfolio, the US biotech major is entering into the hot area of targeted protein degradation to boost its immunology and neurology pipeline.

More from Therapeutic Category

Scrip Data Article Without An Author
Nov 19 2025
"Neque porro quisquam est qui dolorem ipsum quia dolor sit amet, consectetur, adipisci velit..."
Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]
Nov 12 2025
Pipelines in bioconjugates continue to develop, from ADCs to XDCs, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) leading the expansion.
Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC
Nov 12 2025
Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.